Evofem Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>EB</div>
EVFM -- USA Stock  

USD 1.54  0.02  1.28%

While some of us are excited about healthcare space, it makes sense to summarize Evofem Biosciences in greater detail to make a better assessment of its actual value. We will evaluate if Evofem Biosciences shares are reasonably priced going into May. Is current Evofem Biosciences value sustainable? We will go over the firm valuation drivers to give you a better outlook on taking a position in it.
Published over two weeks ago
View all stories for Evofem Biosciences | View All Stories
Should you be concerned about Evofem Biosciences (NASDAQ:EVFM) new valuation?
This firm currently holds 85.94 M in liabilities.
We provide trade advice to complement the prevailing expert consensus on Evofem Biosciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Evofem Biosciences using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evofem Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Evofem Biosciences's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Evofem Biosciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evofem Biosciences. We calculate exposure to Evofem Biosciences's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Evofem Biosciences's related companies.

Evofem Biosciences Investment Alerts

Evofem investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Evofem Biosciences performance across your portfolios.Please check all investment alerts for Evofem

Evofem Biosciences Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Evofem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evofem Biosciences competition to find correlations between indicators driving the intrinsic value of Evofem.

How Evofem utilizes its cash?

To perform a cash flow analysis of Evofem Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Evofem Biosciences is receiving and how much cash it distributes out in a given period. The Evofem Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Evofem Biosciences Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (107.59 Million)

What is driving Evofem Biosciences Investor Appetite?

The company reported the previous year's revenue of 446 K. Net Loss for the year was (142.31 M) with profit before overhead, payroll, taxes, and interest of 78 K.
 2018 2019 2020 2021 (projected)
Current Assets2.48 M26.42 M97.73 M105.45 M
Total Assets4.01 M28.3 M109.97 M118.65 M

Margins Breakdown

Evofem profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Evofem Biosciences itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Evofem Biosciences profit margins.
EBITDA Margin(65.72)
Gross Margin(0.0453)
Profit Margin(76.01)


Evofem Biosciences Average Equity is relatively stable at the moment. Evofem Biosciences Average Assets is relatively stable at the moment. Furthermore, Evofem Biosciences Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Evofem Biosciences Average Equity is increasing over the last 8 years. Evofem Biosciences Average Assets is increasing over the last 8 years. Furthermore, Evofem Biosciences Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years.

Can Evofem Biosciences build up on the new hike?

The skewness is down to -0.78 as of today. Evofem Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evofem Biosciences independently to ensure intended market timing strategies are aligned with expectations about Evofem Biosciences volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Evofem Biosciences' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Evofem Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

When is the right time to buy or sell Evofem Biosciences? Buying stocks such as Evofem Biosciences isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis.
With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor drop any shares of Evofem Biosciences at this time. The Evofem Biosciences risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Evofem Biosciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Evofem Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com